01 February 2004
Autonomic signs and dosing during the initial stages of clozapine therapy
L. Kola Oyewumi, Zack Z. Cernovsky, David J. FreemanMed Sci Monit 2004; 10(2): PI19-23 :: ID: 11587
Abstract
Background:Recent reports implicate clozapine in heart rate variability, QTc prolongation, torsade de pointes and sudden death at therapeutic doses, even in physically healthy patients. This study aims to examine whether autonomic (vital) signs are correlated with clozapine dose titration and blood levels of clozapine and nor-clozapine during clozapine therapy.Material/Methods: Thirty-seven consecutive patients with diagnosis of schizophrenia treated with clozapine were included in this prospective longitudinal study. The study was restricted to only the first 8 weeks of treatment. After obtaining informed consent, serum concentrations of clozapine and nor-clozapine were determined weekly at trough, as doses were administered q12h and adjusted according to clinical guidelines for clozapine use. Autonomic signs including BP (supine and erect), pulse (supine and erect) and temperature were monitored daily each morning before and one hour after the morning’s dose of clozapine was administered.Results: We calculated analyses of covariance (ANCOVAs) to evaluate the changes in vital signs parameters, from baseline to week 8, with clozapine variables as covariates (i.e, the dose of clozapine, as well as the levels of serum clozapine and nor-clozapine). The blood pressure and pulse did not change significantly (p<0.01) from baseline to weeks 8. The temperature was inversely related to clozapine dose (p<0.003). Higher nor-clozapine to clozapine ratios were associated with higher BP measures (p=0.002). The magnitude of these relationships is weak (r<0.30).
Conclusions: There is a tendency to autonomic dysregulation during clozapine use. This has cardiac function implications, justifying cautious dose adjustment with frequent monitoring of vital signs.
Keywords: Analysis of Variance, Antipsychotic Agents - administration & dosage, Antipsychotic Agents - blood, Blood Pressure - drug effects, Blood Pressure - physiology, Body Temperature - drug effects, Clozapine - administration & dosage, Clozapine - analogs & derivatives, Clozapine - blood, Drug Administration Schedule, Drug Monitoring, Heart Rate - drug effects, Heart Rate - physiology, Longitudinal Studies, Prospective Studies, Schizophrenia - blood, Schizophrenia - drug therapy, Schizophrenia - physiopathology, Analysis of Variance, Antipsychotic Agents - blood, Blood Pressure - physiology, Body Temperature - drug effects, Clozapine - blood, Drug Administration Schedule, Drug Monitoring, Heart Rate - physiology, Longitudinal Studies, Prospective Studies, Schizophrenia - physiopathology
Editorial
01 January 2025 : Editorial
Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?DOI: 10.12659/MSM.947707
Med Sci Monit 2025; 31:e947707
In Press
Clinical Research
Impact of Periodontal Treatment on Early Rheumatoid Arthritis and the Role of Porphyromonas gingivalis Anti...Med Sci Monit In Press; DOI: 10.12659/MSM.947146
Clinical Research
C-Reactive Protein, Uric Acid, and Coronary Artery Ectasia in Patients with Coronary Artery DiseaseMed Sci Monit In Press; DOI: 10.12659/MSM.947158
Clinical Research
Effects of Remote Exercise on Physical Function in Pre-Frail Older Adults: A Randomized Controlled TrialMed Sci Monit In Press; DOI: 10.12659/MSM.947105
Database Analysis
Development and Validation of a Competitive Risk Model in Elderly Patients with Transitional Cell Bladder C...Med Sci Monit In Press; DOI: 10.12659/MSM.946332
Most Viewed Current Articles
17 Jan 2024 : Review article 6,964,204
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 700,526
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 24,009
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 18,806
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912